Company research / RMTI

Rockwell Medical, Inc. (RMTI)

SEC name ROCKWELL MEDICAL, INC. · CIK 0001041024 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Rockwell Medical, Inc. reported revenue of $69.26M. Revenue fell 31.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $69.39M.

Key ratios (year ended 2025-12-31)

16.9%
Gross margin
-6.8%
Operating margin
-7.7%
Net margin
-14.4%
Return on year-end equity
-31.8%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-05

Headquarters locality: United States · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-11, first reflected in a filing dated 2022-05-16; 1-for-10, first reflected in a filing dated 2026-08-13. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$69.39M$69.26M$101.49M$83.61M$72.81M$61.93M$62.20M$61.30M$63.39M$57.30Mn/a
Cost of Revenue$57.10M$57.56M$84.00M$74.91M$68.73M$64.35M$59.47M$58.46M$64.97M$53.60M$46.53M
Gross Profit$12.29M$11.70M$17.48M$8.70M$4.08M-$2.42M$2.73M$2.84M-$1.58M$3.70M$6.75M
R&D Expense$40.0K$0$19.0K$1.11M$3.12M$6.83M$7.09M$6.89M$5.64M$6.32M$5.84M
Operating Income-$4.52M-$4.69M$608.0K-$6.67M-$16.78M-$30.34M-$28.42M-$34.52M-$32.44M-$25.92M-$20.21M
Depreciation & Amortization$2.09M$2.19M$2.18M$1.44M$576.0K$668.0K$834.0K$788.0K$650.1K$514.4K$762.4K
EBITDA-$2.43M-$2.50M$2.79M-$5.23M-$16.20M-$29.67M-$27.59M-$33.74M-$31.79M-$25.41M-$19.45M
Net Income-$5.08M-$5.31M-$480.0K-$8.44M-$18.68M-$32.67M-$30.89M-$34.13M-$32.13M-$25.92M-$19.80M
EPS (Diluted)n/a-$0.15-$0.03-$0.37-$1.31-$3.83-$0.41n/an/a-$0.51-$0.39
Total Assets$56.53M$57.15M$59.21M$52.17M$46.63M$48.57M$77.75M$44.32M$52.56M$58.78M$83.15M
Total Liabilities$21.44M$20.16M$26.62M$30.88M$32.53M$46.04M$43.58M$24.00M$25.28M$25.87Mn/a
Shareholders' Equity$35.09M$36.98M$32.59M$21.29M$14.11M$2.54M$34.17M$20.32M$27.28M$32.91M$52.96M
Cash & Equivalents$10.52M$10.71M$15.66M$8.98M$10.10M$13.28M$48.68M$11.79M$22.71M$8.41M$17.18M
Operating Cash Flow$2.90M-$659.0K$4.20M-$9.41M-$16.93M-$33.53M-$29.64M-$27.25M-$20.42M-$21.11M-$12.45M
Capital Expenditures$1.36M$542.0K$1.01M$284.0Kn/an/an/an/an/an/an/a
Free Cash Flow$1.54M-$1.20M$3.19M-$9.70Mn/an/an/an/an/an/an/a
Shares Outstanding3.97M39.41M34.06M29.13M12.16M8.54M93.57M65.38M57.03M51.77M51.53M
Weighted Average Diluted Sharesn/a35.97M31.06M23.32M14.30M8.53M75.62Mn/an/a51.07M50.68M
EPS (Basic)n/a-$0.15-$0.03-$0.37-$1.31-$3.83-$0.41n/an/a-$0.51-$0.39

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView